Glycotope Presents Phase I Results of Novel Glycooptimized Monoclonal anti-TA-MUC1 Antibody PankoMab-GEXTM at European Cancer Congress
Glycotope GmbH /
Glycotope Presents Phase I Results of Novel Glycooptimized Monoclonal
anti-TA-MUC1 Antibody PankoMab-GEXTM at European Cancer Congress
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Berlin, Germany, September 27, 2013 - Glycotope GmbH, a global leader in
optimizing the glycosylation of biopharmaceuticals and carbohydrate-specific
antibodies (GlycoBodies), announced today that it is presenting first-in-human
results of their phase I study of PankoMab-GEX(TM), a glycoengineered antibody
against their novel TA-MUC1 epitope which is tumor-specific and abundantly
present on many solid cancers, at this year's European Cancer Congress (ECCO
17). The annual congress is taking place from September 27 to October 01 in
Amsterdam. Glycotope is participating with a poster presentation in the session
"Drug Development" on Sunday, September 29, 2013, in Hall 4.
Eligible patients with TA-MUC1 positive advanced solid tumors, progressing after
standard treatments, were enrolled into this phase I trial. Primary endpoints
were safety and tolerability. Pharmacokinetics, immunogenicity and anti-tumor
activity were also assessed.
PankoMab-GEX(TM) clearly demonstrated clinical activity as single agent in
heavily pre-treated patients with far advanced cancers and could be safely
administered at all tested doses and schedules with a very favorable safety,
side effect and pharmacokinetic profile.
Poster Presentation
+-------------+----------------------------------------------------------------+
|Poster Title |First-in-human phase I study of PankoMab-GEX(TM), a novel |
| |glycooptimized anti-TA-MUC1 monoclonal antibody |
+-------------+----------------------------------------------------------------+
|Session Title|Drug Development |
+-------------+----------------------------------------------------------------+
|Date and Time|Sunday, September 29, 9.30 am - 12:00 am |
+-------------+----------------------------------------------------------------+
|Location |Amsterdam RAI Exhibition and Convention Centre, Hall 4 |
+-------------+----------------------------------------------------------------+
About PankoMab-GEX(TM)
PankoMab-GEX(TM) is a potent humanized and glycooptimized therapeutic antibody
(IgG1) recognizing the novel carbohydrate-induced conformational TA-MUC1 epitope
expressed on the majority of tumor cells in a wide variety of cancers. The
epitope comprises a tumor-specific carbohydrate antigen together with the
immunodominant peptide region of MUC1, combining high tumor-specificity, high
number of binding sites and affinity. It is abundantly present on primary
tumors, metastasis and cancer stem cells and virtually absent on normal cells.
Main target indications include ovarian, lung, breast and gastrointestinal
tumors, mostly with over 90% of the patients. PankoMab-GEX(TM) expresses a
series of potent anti-tumor modes of action, including antibody dependent
cellular cytotoxicity (ADCC), tumor cell phagocytosis and apoptosis induction,
strongly enhanced by glycooptimization through Glycotope's GlycoExpress(TM)
platform. This allows significantly improved treatment outcome compared to non-
glycooptimized biotherapeutics. Preliminary results of the Phase I single agent
study of PankoMab-GEX(TM) show very good tolerability, safety profile and
pharmacokinetic properties as well as strong signals for high anti-tumor
activity including complete and partial reponses as well as very lasting
clinical benefit in various cancers including ovarian and lung carcinoma.
PankoMab-GEX(TM) is the lead molecule of Glycotopes's GlycoBody technology which
represents the Company's treasure box of more than 200 monoclonal antibodies.
About Glycotope
Glycotope, founded in 2001 in Berlin, focuses on the development of innovative
antibodies for the treatment of various cancer types. These GlycoBodies(TM)
target glycostructures on cell surfaces. In addition, Glycotope develops so-
called BioSuperiors, antibody and non-antibody recombinant biopharmaceuticals
with optimized and fully human sugar structures for clinical superiority. Key to
the glycooptimization technology is a toolbox of glycoengineered proprietary
human cell lines that allow the glycooptimization of proteins in respect to a
whole series of different determining sugars and is based on fully human
glycosylation. GlycoExpress(TM) allows the selection of the most appropriate and
best suitable human glycoform of a product and a high yield production superior
in reproducibility, quality and yield. Glycooptimization via GlycoExpress(TM)
provides improved efficacy, bioavailability, immunogenicity and broadens the
potential patient populations and indications, as well as providing a much
improved cost-effectiveness. Glycotope has currently four products in clinical
development from late stage Phase I to late stage Phase II. The Company's
additional pipeline includes preclinical non-antibody and antibody
biopharmaceuticals for various indications.
Together with its subsidiary Glycotope Biotechnology in Heidelberg, Glycotope
has evolved into a leading fully integrated glycobiology company, covering the
entire workflow from discovery, molecule optimization, clone and process
development, preclinical and clinical drug development to GMP production. With
more than 160 employees and a strong and broad IP-platform, Glycotope today is
one of the largest biotechnology companies in Germany.
Contact:
Glycotope GmbH
Dr. Steffen Goletz, CEO & CSO
Robert-Roessle-Str. 10, D-13125 Berlin, Germany
Phone: +49-(0)30 94 89-2600
Fax: +49-(0)30 94 89-2609
Email: steffen.goletz@glycotope.com
Website: www.glycotope.com
Press Release PDF:
http://hugin.info/157017/R/1732042/579388.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Glycotope GmbH via Thomson Reuters ONE
[HUG#1732042]